Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stockCohance Lifesciences Ltd (COHANCE) is currently trading at 426.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Cohance Lifesciences is an integrated CDMO providing custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs, formulated drugs, ADC payloads and oligonucleotide building blocks for global pharma, biotech and specialty-chemical innovators, with manufacturing and R&D facilities across India and a presence in New Jersey supporting advanced modalities. The company is in a transition phase with FY26 impacted by customer-led de-stocking and timing shifts, leading to an early-to-mid double-digit revenue decline guidance while management expects recovery and return to growth in FY27 as Phase III and commercial programmes convert for Cohance Lifesciences. Advanced modality investments remain strategic: Cohance is the exclusive ADC payload intermediate supplier to a major innovator, has filed new ADC DMFs, and is commissioning a USD 10m US cGMP expansion to support Phase 2b supply, underscoring continued focus on high-value, differentiated technology platforms. Operationally Cohance generated free cash flow and retained net cash of INR 1.76 billion in 9MFY26 despite capex of INR 1.61 billion towards oligo and capacity expansion, demonstrating resilient cash generation while absorbing integration and remediation costs. Quality and governance actions are central: the company embedded senior quality leadership, engaged external advisors after an OAI→Warning Letter event at Nacharam FDF, and reports OTIF above 95%, positioning quality remediation and regulatory engagement as enablers for future scale at Cohance Lifesciences.
Over the past 52 weeks, Cohance Lifesciences Ltd has traded between a low of ₹267.85 and a high of ₹1,038.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Cohance Lifesciences Ltd has a market capitalization of approximately 16,442.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Cohance Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 91.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,442.74 Cr, Cohance Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Cohance Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 91.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Biopharma Shakti is a new initiative with a ₹10,000 crore outlay over five years aimed at making India a global hub for biopharma manufacturing, focusing on biologics and biosimilars.
Bearish
5
Neutral
7
Bullish
2
Bearish
27
Neutral
7
Bullish
12
Bearish
22
Neutral
0
Bullish
10
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1402.85 | 19,400 Cr | 31.32 | 4.97 | 0.51 | 15.87 | 13.27 | 8.79 | ||
1690.10 | 19,371 Cr | -398.49 | 3.32 | 0.00 | -1.10 | 0.55 | -0.59 | ||
925.25 | 16,606 Cr | 11.71 | 1.80 | 0.54 | 15.38 | 15.37 | 12.39 | ||
426.45 | 16,443 Cr | 91.74 | 4.20 | 0.00 | 5.05 | 5.47 | 2.62 | ||
814.90 | 16,009 Cr | 23.73 | 2.82 | 1.47 | 11.89 | 10.81 | 7.66 | ||
975.00 | 15,584 Cr | 39.11 | 2.20 | 0.51 | 5.62 | 6.41 | 2.56 | ||
1134.25 | 13,876 Cr | 24.58 | 4.16 | 0.44 | 16.94 | 22.33 | 14.17 | ||
| Median: 7 Co. | — | 975.00 | 16,443 Cr | 24.58 | 3.32 | 0.51 | 11.89 | 10.81 | 7.66 |
Regulatory/Compliance Filing
Nomination & Remuneration Committee approved ESOP 2026 (in-principle approvals taken on record), grant of up to 1,97,48,317 options, grant of 1,74,843 options under ESOP 2023, cancellation of 1,87,703 grants and allotment of 30,190 shares.
Regulatory/Compliance Filing
Cohance Lifesciences' Nomination & Remuneration Committee approved ESOP 2026 in‑principle approvals, grant of up to 1,97,48,317 options, grants under ESOP 2023, allotment of 30,190 shares and cancellation of 1,87,703 ESOP 2023 grants.
Earnings Call/Transcript
Cohance Lifesciences will host a conference call for investors and analysts on 2026-08-05 at 18:30 IST to discuss unaudited Q1 FY27 results (quarter ended 30 June 2026).
Earnings Call/Transcript
Cohance Lifesciences to host Q1 FY27 results conference call on 2026-08-05 at 18:30 IST for investors and analysts; results to be announced earlier same day. Registration via provided Chorus Call link.
Board Meeting
Cohance Lifesciences Ltd will hold a Board meeting on 2026-08-05 to consider and approve unaudited standalone and consolidated financial results for quarter ended 2026-06-30. Trading window closed until 2026-08-07.
Board Meeting
Cohance Lifesciences Ltd will hold a Board meeting on 05-08-2026 to consider and approve the unaudited standalone and consolidated financial results for quarter ended 30 June 2026; trading window closed until 07-08-2026.
Cohance Lifesciences is an integrated CDMO providing custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs, formulated drugs, ADC payloads and oligonucleotide building blocks for global pharma, biotech and specialty-chemical innovators, with manufacturing and R&D facilities across India and a presence in New Jersey supporting advanced modalities.
The company is in a transition phase with FY26 impacted by customer-led de-stocking and timing shifts, leading to an early-to-mid double-digit revenue decline guidance while management expects recovery and return to growth in FY27 as Phase III and commercial programmes convert for Cohance Lifesciences.
Advanced modality investments remain strategic: Cohance is the exclusive ADC payload intermediate supplier to a major innovator, has filed new ADC DMFs, and is commissioning a USD 10m US cGMP expansion to support Phase 2b supply, underscoring continued focus on high-value, differentiated technology platforms.
Operationally Cohance generated free cash flow and retained net cash of INR 1.76 billion in 9MFY26 despite capex of INR 1.61 billion towards oligo and capacity expansion, demonstrating resilient cash generation while absorbing integration and remediation costs.
Quality and governance actions are central: the company embedded senior quality leadership, engaged external advisors after an OAI→Warning Letter event at Nacharam FDF, and reports OTIF above 95%, positioning quality remediation and regulatory engagement as enablers for future scale at Cohance Lifesciences.
Pharmaceuticals & Biotechnology
Pharmaceuticals
16,297 Cr
Low Risk
90.9
37.2
1.6
4.2
1,038.00
267.85
Sales CAGR
Profit CAGR
ROE
ROCE
